Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide in Alcohol Use Disorder and Obesity
NCT07772960Phase 1Recruiting
- Sponsor
- Yale University
- Start
- Oct 2026
- Primary completion
- Oct 2031
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of semaglutide in alcohol use disorder (AUD) (3 arms), sponsored by Yale University. Primary endpoint: Alcohol use days at 20 weeks. Started Oct 2026; status: recruiting.
02
Drugs
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT07772960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07772960.